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Abstract
Background: Cadherin-like protein 22 (CDH22) is a transmembrane glycoprotein involved in cell-cell adhesion and
metastasis. Its role in cancer is controversial because it has been described as being upregulated in colorectal
cancer, whereas it is downregulated in metastatic melanoma. However, its status in breast cancer (BC) is unknown.
The purpose of our study was to determine the molecular status and clinical value of CDH22 in BC.
Results: We observed by immunohistochemistry that the level of CDH22 expression was lower in BC tissues than in
their matched adjacent-to-tumour and non-neoplastic tissues from reduction mammoplasties. Since epigenetic
alteration is one of the main causes of gene silencing, we analysed the hypermethylation of 3 CpG sites in the
CDH22 promoter by pyrosequencing in a series of 142 infiltrating duct BC cases. CDH22 was found to be
hypermethylated in tumoral tissues relative to non-neoplastic mammary tissues. Importantly, this epigenetic
alteration was already present in adjacent-to-tumour tissues, although to a lesser extent than in tumoral samples.
Furthermore, CDH22 gene regulation was dynamically modulated in vitro by epigenetic drugs. Interestingly, CDH22
hypermethylation in all 3 CpG sites simultaneously, but not expression, was significantly associated with shorter
progression-free survival (p = 0.015) and overall survival (p = 0.021) in our patient series. Importantly, CDH22
hypermethylation was an independent factor that predicts poor progression-free survival regardless of age and
stage (p = 0.006).
Conclusions: Our results are the first evidence that CDH22 is hypermethylated in BC and that this alteration is
an independent prognostic factor in BC. Thus, CDH22 hypermethylation could be a potential biomarker of poor prognosis
in BC.
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Background
Breast cancer (BC) is the most frequent type of cancer
among women and one of the leading causes of cancer-
related deaths worldwide [1, 2]. In recent years, an increase
in overall survival (OS) has been achieved, mainly due to
advances in early detection programmes and therapeutic
strategies, although its incidence remains high [2]. BC origi-
nates from the accumulation of genetic and epigenetic ab-
normalities in tumour suppressor genes and oncogenes [3].
A thorough understanding of the mechanisms responsible
for BC onset and progression is needed to develop prog-
nostic biomarkers and efficient targeted therapies.
BC comprises five major pathological subtypes:
luminal A-like, luminal B-like (HER2-negative), luminal
B-like (HER2-positive), HER2-positive (non-luminal) and
triple-negative. This classification is based on immuno-
histochemical biomarkers (oestrogen, progesterone and
HER2 receptors, and Ki-67), as confirmed in the last St
Gallen International Expert Consensus [4]. However,
these subtypes are heterogeneous and patients within a
subtype can display a differential prognosis [5], so new
prognostic biomarkers are still needed to stratify BC
patients with good and poor outcomes [6].
Epigenetic alterations are common molecular abnormal-
ities in cancer, including DNA methylation, alterations in
microRNA profiling, and post-translational modifications
of histones [7, 8]. Aberrant DNA methylation is one of the
most frequent molecular abnormalities in BC [9].
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Methylation of certain genes has been linked to clinical
and pathological characteristics of breast tumours and is
considered to be a biomarker of diagnosis [10], hormone
receptor [11] and HER2 [12] status, response to tamoxifen
[11] and chemotherapy [13], metastases during follow-up
[9] and a predictor of survival [11, 14].
The CDH22 gene, first described by Sugimoto et al.
[15], is located on chromosome 20 and has 15 exons. It
encodes a transmembrane glycoprotein of the cadherin
family (known as CDH22 or PB-cadherin) that is
involved in cell-cell adhesion. It has been found to par-
ticipate in morphogenesis and tissue formation in neural
and non-neural cells of the brain and neuroendocrine
organs [16–18]. The expression of members of the cad-
herin family may affect tumorigenesis or metastasis of
various cancers, and these proteins may serve as import-
ant biomarkers [16]. However, this gene has not been
previously studied in BC. Our aim was to determine the
molecular status and clinical value of CDH22 in BC.
Results
CDH22 protein level is lower in BC tissues than in non-
neoplastic tissues
In order to examine the CDH22 expression pattern in BC,
we measured its protein level by immunohistochemistry
in a series of 88 BC cases and their adjacent-to-tissue
counterparts, along with 24 non-neoplastic samples from
reduction mammoplasties. Overall, there was a signifi-
cantly lower level of expression in tumour cells than in
non-neoplastic cells (p < 0.001, Fig. 1). It is important to
note that the adjacent-to-tumour tissue expressed an
intermediate protein expression level, between the non-
neoplastic and the tumour tissue. These results show for
the first time the cytoplasmic protein expression pattern
of CDH22 in BC and indicate that it is downregulated in
this malignancy.
The CDH22 gene promoter is hypermethylated in BC
Since DNA methylation is one of the main mechanisms
of gene silencing, we investigated the methylation status
of the CDH22 gene. Five CpG sites in the CDH22 pro-
moter were examined by pyrosequencing in a larger
series of 142 BC cases (Table 1), 26 paired adjacent-to-
tumour tissues and 19 non-neoplastic breast samples
from reduction mammoplasties. The CDH22 promoter is
enriched in poly-T sequences (Additional file 1: Figure S1),
which makes it difficult to conduct successful pyrosequenc-
ing reactions of good quality. Especially, the presence of a
poly-T very close to the second CpG introduced a large
number of errors that hampered to analyse the methylation
status of this second and subsequent CpG sites. To
overcome this situation, two sequencing primers were
used to gain coverage by sequencing more CpG sites
in the region. Thus, methylation in CpG1 was
analysed with a forward-sequencing primer, while
CpG4 and CpG5 were examined with a reverse-
sequencing primer (Additional file 2: Figure S2).
Since pyrosequencing provides a quantitative measure
of methylation, the optimal cut-off value distinguishing
the unmethylated from the methylated status of each of
the CpG sites was estimated by ROC curve analysis as
being 17.5, 40 and 66.5% methylation for CpG1, CpG4
and CpG5, respectively, (Table 2 and Additional file 3:
Figure S3). Additionally, we also considered that a case
had hypermethylated CDH22 when the three tested CpG
sites simultaneously showed methylation percentages
above their cut-off values.
Based on this threshold, higher hypermethylation
levels in all CpG sites were observed in tumours than in
non-neoplastic tissues, again with intermediate levels in
adjacent-to-tumour samples (Fig. 2a). This is the first
evidence showing that CDH22 is epigenetically silenced
by promoter hypermethylation in BC.
Next, we interrogated whether CDH22 promoter
methylation levels were correlated with protein expres-
sion. Methylation in only the CpG4 site was significantly
correlated with immunohistochemical expression (Fig. 2b).
However, the statistical significance was lost when consid-
ering methylation in all studied CpG sites.
CDH22 expression can be modulated by epigenetic drugs
in BC cell lines
To test whether CDH22 expression can be dynamically
modulated by epigenetic mechanisms, a panel of six BC
cell lines and one immortalised but non-neoplastic
mammary cell line (HBL-100) were treated with two epi-
genetic drugs (AZA and TSA). Although a slight de-
crease in CDH22 methylation was observed in some cell
lines upon treatment with AZA+TSA, a very strong re-
expression of CDH22 mRNA was found by qRT-PCR in
all tested cell lines following epigenetic drug treatment
(Fig. 2c). These results suggest that epigenetic treat-
ments can restore CDH22 expression and that this can
be dynamically modulated in vitro in BC.
CDH22 hypermethylation predicts BC progression
Lastly, we attempted to examine the clinical value of
CDH22 hypermethylation in our series of 142 BC pa-
tients (Table 1). Using the aforementioned cut-off values,
we found that CDH22 hypermethylation in all the 3
CpG sites was significantly associated with shorter
progression-free survival (PFS) (p = 0.015) and OS (p =
0.021) (Fig. 3 and Additional file 4: Figure S4).
Although subtle correlation between protein expres-
sion and methylation has been observed in our series,
the relationship between immunohistochemical CDH22
protein levels and PFS or OS was examined: no signifi-
cant association was found between them, although high
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levels of protein tended to be associated with longer PFS
and OS (Additional file 5: Figure S5).
It is well known that several factors, such as BC
subtype, lymph node involvement, grade and stage
can influence BC prognosis. As expected, these char-
acteristics had an important influence on PFS and OS
(Additional file 6: Figure S6). Therefore, the independ-
ent impact of CDH22 hypermethylation on progression
and survival, regardless of those clinical variables, was
tested in a Cox regression model. It is of particular note
that we found that hypermethylation in the CDH22 pro-
moter was still significantly associated with shorter PFS
(p = 0.006), irrespective of age and stage (Table 3). The
other clinical parameters significantly correlated with PFS
and OS (grade and lymph node involvement) were not in-
cluded in the Cox regression model due to their associ-
ation with the stage (p < 0.001). CDH22 hypermethylation
had a hazard ratio of 4.2 for PFS (Table 3). These results
suggest that CDH22 hypermethylation is an independent
predictor of progression in BC.
Discussion
This study explored the unknown molecular status and
clinical value of CDH22 deregulation in BC, which have
been described in other cancer types [16, 17]. We
provide the first evidence of the low level of expression
of CDH22 in breast tumoral cells compared with non-
neoplastic mammary tissue. The exact role of this pro-
tein in cancer is controversial. Thus, a lower level of
CDH22 protein expression has been reported in meta-
static melanoma than in dysplastic nevus [16].
Conversely, mRNA and protein overexpression were de-
scribed in primary and metastatic colorectal cancer rela-
tive to normal mucosa [17]. These observations suggest
that the role of CDH22 in cancer development and me-
tastasis is likely to be tissue type-specific [16]. This dis-
crepancy might be explained by the two opposing roles
of cell adhesion molecules: to prevent cells from metas-
tasizing by increasing cell-cell adhesion at the site of the
primary tumour and to enhance metastatic potential by
increasing their anchorage to other cells at distant loca-
tions in the body after breaking off from the primary
tumour [16, 19]. E-cadherin provides an example of this
potential dual tissue-specific role, since it is lost in ma-
lignant epithelial cancers, and simultaneously is essential
from promoting tumorigenesis in certain cancer types,
including ovarian cancer [20] and inflammatory BC [21].
Despite its controversial role, no studies have exam-
ined the mechanisms underlying CDH22 deregulation in
cancer. Thus, it has been suggested that mutations,
Fig. 1 CDH22 protein expression in breast tissues. CDH22 protein expression was measured by immunohistochemistry in 88 pairs of breast tumoural and
adjacent-to-tumour tissues, along with 24 non-neoplastic samples from reduction mammoplasties. Expression levels were scored as 0, no expression; 1,
weak expression; 2, intermediate expression; and 3, strong expression (*p< 0.001). Images were acquired using a Leica 4000B microscope (Leica, Wetzlar,
Germany) at ×200 magnification. Contingency table shows the association between the tissue type and CDH22 immunohistochemical expression
Martín-Sánchez et al. Clinical Epigenetics  (2017) 9:7 Page 3 of 8
epigenetic silencing and increased proteolysis may be in-
volved in the loss of CDH22 expression [16]. In this
study, we have provided the first evidence that CDH22
downregulation in BC relative to non-neoplastic mam-
mary tissues is due to promoter hypermethylation in a
subset of cases. Additionally, we have observed that
CDH22 silencing is dynamically restored in vitro by epi-
genetic drug treatment in a very similar manner in all
BC cell lines. This epigenetic alteration has been
assessed by pyrosequencing, a technique that yields a
quantitative measure of methylation, in contrast to the
qualitative technique of methylation-specific PCR [22]. It
is worth noting, as reported by other authors [23, 24],
that a poly-T-enriched region in this gene promoter has
compromised polymerase fidelity, making it difficult to
analyse the rest of the gene promoter in several cases.
Importantly, CDH22 hypermethylation was signifi-
cantly associated with shorter PFS and OS in our
large series of BC patients. Accordingly, CDH22 de-
regulation was associated with clinical outcome in
other cancer types: loss of CDH22 protein expression
was correlated with melanoma progression, and with
worse 5-year PFS, and a similar, though not signifi-
cant pattern, was observed for 5-year OS [16]; in
colorectal cancer CDH22 overexpression was signifi-
cantly and positively correlated with progression, in-
vasion, metastasis and clinical stage of patients [17].
Above all, we showed that CDH22 hypermethylation,
but not expression, was an independent prognostic
factor in our BC series. It can predict shorter PFS,
regardless of the key factors of age and stage in BC
outcome, by using a quantitative and objective
method like pyrosequencing in comparison with
immunohistochemistry.
Conclusions
In conclusion, our results show that CDH22 is hyper-
methylated in BC, and that this epigenetic alteration
is an independent biomarker predicting shorter PFS
in BC.
Table 1 Pathological and clinical characteristics of BC patient series
Variable Frequency (%)
BC subtype
LA 20/142 (14.1)
LB 44/142 (31.0)
LH 33/142 (23.2)
H 21/142 (14.8)
TN 24/142 (16.9)
Grade
I 25/142 (17.6)
II 59/142 (41.5)
III 58/142 (40.8)
Lymph node involvement
No 68/139 (48.9)
Yes 71/139 (51.1)
Stage
I 49/138 (35.5)
IIA 34/138 (24.6)
IIB 27/138 (19.6)
IIIA 19/138 (13.7)
IIIC 9/138 (6.5)
Age (years) Mean 60
Range 30–95
Tumour size (cm) Mean 2.2
Range 0.3–10.0
Progression-free survival (months) Mean 82.9
Range 1–208
No 115/141 (81.6)
Yes 26/141 (18.4)
Overall survival (months) Mean 86.9
Range 1–208
Exitus 27/140 (19.3)
Chemotherapy
No 49/138 (35.5)
Yes 89/138 (64.5)
Hormone therapy
No 43/136 (31.6)
Yes 93/136 (68.4)
BC subtypes: LA luminal A, LB luminal B/HER2-negative, LH luminal B/HER2-
positive, H HER2, TN triple-negative
Table 2 CDH22 hypermethylation in our series of patients
Parameter Number
Breast tumours n = 142
Median % CpG1 methylation (range) 9.0 (1–100)
Median % CpG4 methylation (range) 58.0 (0–74)
Median % CpG5 methylation (range) 65.0 (2–98)
Adjacent-to-tumour tissues n = 26
Median % CpG1 methylation (range) 2.0 (0–98)
Median % CpG4 methylation (range) 9.0 (0–57)
Median % CpG5 methylation (range) 28.0 (3–70)
Non-neoplastic breast samples n = 19
Median % CpG1 methylation (range) 5.0 (0–27)
Median % CpG4 methylation (range) 8.0 (0–33)
Median % CpG5 methylation (range) 9.5 (3–30)
Cut-off values (%)
CpG1 17.5
CpG4 40.0
CpG5 66.5
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Methods
Patient samples
We analysed a series of 142 formalin-fixed, paraffin-
embedded samples from BC patients, diagnosed with infil-
trating duct carcinoma breast between 1996 and 2006 in
the Department of Pathology (Complejo Hospitalario de
Navarra, Navarra Public Health System, Pamplona, Spain),
upon microscopic evaluation by two independent ob-
servers in accordance with the recommended criteria of
the St Gallen International Expert Consensus 2013 [4] and
considering a Ki-67 threshold of 14% [25], graded accord-
ing to the Nottingham system [26] and staged with AJCC
Fig. 2 Molecular status of CDH22 in BC. a Methylation in three CpG sites was examined by pyrosequencing in a series of 142 BC cases, along with
matched adjacent-to-tumour tissues (n = 26), and non-neoplastic mammary tissues from reduction mammoplasties (n = 19). The horizontal line in each
group represents the median of the series (*p < 0.001). b Contingency table showing association between CDH22 immunohistochemical expression
and the CpG site methylation status in our series of BC patients (*p = 0.01). c CDH22 expression was restored by epigenetic drugs in six BC cell lines
and the immortalised but non-neoplastic mammary cell line HBL-100, as measured by qRT-PCR. 293T cells were used as a positive control
Fig. 3 Clinical value of CDH22 hypermethylation in BC. Significant associations between CDH22 hypermethylation in all three examined CpG sites
and progression-free survival and overall survival were found in our series of BC cases
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system [27]. All tumours were surgically removed and
staged according to their size, histological grade and de-
gree of lymph node involvement. None of the patients had
received radiotherapy or chemotherapy before surgery.
Pathological and clinical characteristics are summarised in
Table 1. All cases were chosen on the basis of them har-
bouring at least 70% tumour cells. Additionally, 88 paired
non-neoplastic adjacent-to-tumour tissues and 24 non-
neoplastic mammary samples from reduction mammo-
plasties were employed.
Immunohistochemistry
Three-micrometer sections of 88 BC tumours and their
non-neoplastic adjacent-to-tumour counterparts, along
with 24 non-neoplastic mammary samples were placed
on slides and then deparaffinized, hydrated and treated
to block endogenous peroxidase activity. After incubat-
ing with the primary rabbit polyclonal CDH22 antibody
(ab171616, Abcam, Cambridge, UK) at 1:100 dilution for
20 min (antigen retrieval at 90 °C for 20 min, pH = 6.0),
the antibody was developed using a Bond Polymer
Refine Detection kit (Leica, Wetzlar, Germany) and
visualised with diaminobenzidine. The pattern of expres-
sion was blind-evaluated by two independent observers.
The intensity of expression was ascribed to one of four
categories: 0, no expression; 1, weak expression; 2, inter-
mediate expression; and 3, strong expression. Images
were acquired with a Leica DM 4000B microscope
(Leica, Wetzlar, Germany).
Cell lines and treatments
A panel of six human BC cell lines (T-47D, BT-474,
BT-549, MDA-MB-468, Hs 578 T and MCF-7) and one
immortalised but non-neoplastic mammary epithelial
cell line (HBL-100) were used in this study. T-47D,
BT-474, BT-549 and HBL-100 cell lines were purchased
from the American Type Cell Collection (ATCC,
Rockville, MD, USA). MDA-MB-468 and MCF-7 cell
lines were obtained from the Leibniz Institute DSMZ-
German Collection of Microorganisms and Cell Cultures
(Braunschweig, Germany). The Hs 578T cell line was
kindly provided by Dr Javier Benítez (Human Genetics
Group, Spanish National Cancer Research Centre,
Madrid, Spain). The human embryonic kidney 293T cells
(ATCC, Rockville, MD, USA) were used as a positive
control for CDH22 expression. All cell lines used were
grown in RPMI-1640 or DMEM supplemented with 10%
foetal bovine serum and 1% penicillin/streptomycin (all
from Life Technologies, Carlsbad, CA, USA), at 37 °C in
a humidified atmosphere with 5% CO2.
BC cell lines were treated with two epigenetic drugs:
the demethylating agent 5-aza-2′-deoxycytidine (AZA)
and the histone deacetylase inhibitor trichostatin A
(TSA) (both from Sigma-Aldrich, St Louis, MO, USA).
Briefly, cells were seeded at a density of 1 × 105 cells/ml,
allowed to attach overnight and treated with 4 μM AZA
for 72 h by adding the drug every 24 h, 300 nM TSA for
24 h or the combination of both drugs for the last 24 h,
using PBS as the vehicle control.
DNA extraction, bisulphite conversion and pyrosequencing
To determine the methylation status of the CDH22 gene,
DNA was extracted from formalin-fixed, paraffin-
embedded breast tumours, adjacent-to-tumour tissues and
non-neoplastic mammary tissues using a QIAamp DNA
FFPE Tissue kit (Qiagen, Hilden, Germany). Bisulphite con-
version of DNA was performed to transform unmethylated
cytosines into thymidines, while methylated cytosines
remained intact. Five hundred nanograms of DNA were
treated with freshly prepared bisulphite using the EZ DNA
Methylation-Gold kit (Zymo Research, Irvine, CA, USA) in
accordance with the manufacturer’s recommendations.
Pyrosequencing was carried out to analyse the methylation
of five CpG sites in the promoter of the CDH22 gene
(Additional file 1: Figure S1). For this purpose, first, PCR
amplification was performed using Immolase DNA poly-
merase (BioLine, London, UK) in a final volume of 30 μl
containing 2 μl of bisulphite-modified DNA and two sets of
primers (i) forward primer 5′-GGTTTTTGATGGAA
AGGGAAGGTTTTTA-3′, reverse primer 5′-BIOTIN-CC
AAACAACACCTAAACAACTCCAAAAT-3′, (ii) forward
primer 5′-BIOTIN-GGTTTTTGATGGAAAGGGAAGGT
TTTTA-3′, reverse primer 5′-CCAAACAACACCTAAAC
AACTCCAAAAT-3′). Amplification conditions were initial
Table 3 CDH22 hypermethylation as an independent prognostic factor
Variable PFS OS
Hazard ratio
(95% CI)
p value Hazard ratio
(95% CI)
p value
Age 1.035
(1.005–1.067)
0.021 1.060
(1.026–1.094)
<0.001
Stage 4.149
(1.762–9.772)
0.001 2.450
(0.930–6.453)
0.070
CDH22 hypermethylation 4.289
(1.507–12.209)
0.006 2.498
(0.821–7.601)
0.107
Cox regression model shows the independent effect of each prognostic factor on progression-free survival (PFS) and overall survival (OS). Stage was divided into
two categories: early (stages I, IIA and IIB) and advanced (stages IIIA and IIIC). CI confidence interval
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DNA polymerase activation at 95 °C for 10 min followed by
50 cycles at 95 °C for 30 s, 67 °C for 30 s and 72 °C for 30 s,
and final extension at 72 °C for 7 min. The amplicons were
resolved by electrophoresis using 2% (w/v) agarose gel in
1 × tris-borate-EDTA buffer, stained using SYBR Red Safe
(Life Technologies, Carlsbad, CA, USA) and visualised in a
standard transilluminator (ChemiDoc XRS, Bio-Rad
Laboratories, Hercules, CA, USA). Quantitative DNA
methylation analysis was done as follows: 20 μl of PCR
products were immobilised with Streptavidin Sepharose HP
Beads (GE Healthcare Bio-Sciences, Pittsburgh, PA, USA)
using a Vacuum Prep Work station. Two different se-
quencing primers (one forward 5′-GTTTTTAGT
TTTGGTAGGAT-3′ for the amplicons generated with
the first set of PCR primers and one reverse 5′-
ACACCTAAACAACTCCA-3′ for the amplicons of
the second set of PCR primers) were then annealed
at 80 °C for 2 min in different reactions and pyrose-
quenced in a PyroMark Q24 using PyroMark Gold
Q24 reagents and PyroQ-CpGTM Software (v.1.0.11)
(all from Qiagen, Hilden, Germany). Results were
analysed with PyroMark Q24 software in CpG ana-
lysis mode. Only methylation values found to be of
high quality were considered.
RNA extraction and quantitative reverse transcription PCR
Quantitative reverse transcription PCR (qRT-PCR) was per-
formed to assess the restoration of CDH22 expression by
AZA+TSA treatment in BC cell lines. Briefly, total RNA
was extracted and purified using an RNeasy Mini Kit
(Qiagen, Hilden, Germany) following the manufacturer’s in-
structions. Five hundred nanograms of total RNA were
retrotranscribed using a PrimeScript™ RT reagent Kit
(TaKaRa, Otsu, Japan) under conditions of 37 °C for 15 min
and 85 °C for 5 s. One microliter of the resulting cDNA was
placed in a 96-well plate with 0.5 μl TaqMan probes
(CDH22, Hs.PT.58.50475831; GAPDH, Hs.PT.58.40035104
and ACTB, Hs.PT.39a.22214847 from IDT, Coralville, Iowa,
USA; and 18S, Hs99999901_s1, from Life Technologies,
Carlsbad, CA, USA) and 19 μl of the Premix Ex Taq™ kit
(TaKaRa, Otsu, Japan). PCR amplification was performed in
triplicate using the Quant Studio 12 K Flex (Life Technolo-
gies, Carlsbad, CA, USA) under thermal cycler conditions of
95 °C for 30 s and 40 cycles at 95 °C for 5 s and 60 °C for
34 s. The cycle threshold (Ct) values were calculated using
Quant Studio software (Life Technologies, Carlsbad, CA,
USA). The relative quantification (RQ) was calculated fol-
lowing the ΔCt method (RQ= 2−ΔCt), using GAPDH, ACTB
or 18S as the endogenous control genes. Among them,
GAPDH was found to be the better endogenous gene in our
cell lines, with a smaller coefficient of variation. Therefore,
relative expression of CDH22 was normalised with respect
to the level of GAPDH expression.
Statistical analysis
Demographic, clinical and pathological data were sum-
marised as frequencies (and percentages) or means and
medians (and ranges), as appropriate. The differences in
the frequency of immunohistochemical expression in
non-neoplastic, adjacent-to-tumour, and tumour groups
were evaluated by the Fisher’s exact test. The optimal
cut-off value identifying the methylated or unmethylated
status of the CDH22 gene promoter and predicting PFS
and OS was estimated by ROC curve analysis, as previ-
ously described [28]. Statistical differences in CpG site
methylation between groups were determined by Mann–
Whitney’s test. Kaplan–Meier plots and log-rank tests
were used to examine the association between CDH22
methylation or expression and PFS and OS. A multivari-
ate Cox regression model was fitted to test the inde-
pendent contribution of each variable to the patient’s
outcome after adjustment. Hazard ratios and 95% confi-
dence intervals were used to estimate the effect of each
variable on the outcome. Associations between clinical
variables were tested by the χ2 test.
Additional files
Additional file 1: Figure S1. The CDH22 gene promoter. Bisulphite-
converted sequence of the CDH22 promoter, highlighting the five CpG
sites studied. (TIF 570 kb)
Additional file 2: Figure S2. Representative pyrograms of the CDH22
promoter in breast tissues. Pyrosequencing was conducted with two
sequencing primers to obtain high quality results of methylation percentages
in more CpG sites. Blue, yellow and red boxes indicate high, acceptable and
unacceptable quality results. (TIF 1863 kb)
Additional file 3: Figure S3. Cut-off value for CDH22 methylation. ROC
curve analysis was used to estimate the optimal cut-off values of each of
the CpG site methylation able to distinguish the unmethylated or methylated
status of the CDH22 gene promoter. Here ROC curves for the CpG1 site are
shown. (TIF 407 kb)
Additional file 4: Figure S4. Association between individual CpG site
hypermethylation and clinical parameters in BC. Among the three CpG
sites analysed, the hypermethylation only of the CpG1 was found to be
statistically associated with a poor progression-free survival and shorter
overall survival. (TIF 392 kb)
Additional file 5: Figure S5. Clinical value of CDH22 protein expression
in BC. Associations between CDH22 protein levels and progression-free
survival and overall survival were examined in our series of 88 BC cases.
(TIF 273 kb)
Additional file 6: Figure S6. Clinical value of factors of importance in
BC. Associations between progression-free or overall survival and BC subtype
(LA, luminal A; LB, luminal B/HER2-negative; LH, luminal B/HER2-positive; H,
HER2; TN, triple-negative), lymph node involvement, histological grade and
stage were analysed in our series of 142 BC patients. (TIF 521 kb)
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